Royalty Pharma (RPRX) Cash from Investing Activities (2019 - 2026)

Royalty Pharma has disclosed Cash from Investing Activities across 8 years of filings, most recently posting -$477.9 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$477.9 million, down 194.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 24.35% YoY), and the FY2025 annual result was -$1.6 billion, up 39.73% from the prior year.
• Cash from Investing Activities came in at -$477.9 million for Q1 2026 at Royalty Pharma, up from -$847.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $503.9 million in Q1 2025 to a low of -$1.4 billion in Q3 2022.
• The 5-year median for Cash from Investing Activities is -$477.9 million (2026), against an average of -$463.1 million.
• Across the five-year window, Cash from Investing Activities plunged 5102.47% in 2023 and soared 681.55% in 2025, its largest moves.
• Royalty Pharma's Cash from Investing Activities stood at $414.7 million in 2022, then tumbled by 341.16% to -$1.0 billion in 2023, then jumped by 49.45% to -$505.6 million in 2024, then sank by 67.69% to -$847.8 million in 2025, then surged by 43.63% to -$477.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$477.9 million (Q1 2026), -$847.8 million (Q4 2025), and -$958.3 million (Q3 2025), per Business Quant data.